Introduction {#s0005}
============

Within low-income, ethnic minority neighborhoods, community health workers (CHWs) address various social determinants of health that may complicate diabetes self-management. CHWs are well positioned to address many issues such as language barriers, limited transportation options, poor health literacy, and lack of social support that adversely affect health [@b0005]. CHWs assist patients in understanding medication instructions, arranging transportation to and from appointments, and promoting patient self-efficacy and confidence [@b0010], [@b0015]. Available evidence suggests that CHWs reduce hospitalizations, emergency department visits, and urgent care visits [@b0020], [@b0025]. However, the effect of CHWs on the frequency of routine, ambulatory healthcare utilization remains poorly characterized. We conducted a secondary analysis of a randomized, controlled trial involving CHWs [@b0030] to determine whether CHW support affects ambulatory healthcare utilization among Hispanic and African-American patients with uncontrolled type 2 diabetes, as well as identify predictors of utilization among patients receiving CHW support.

Material and methods {#s0010}
====================

A randomized, controlled trial evaluated the impact of CHWs supporting clinical pharmacists in diabetes management [@b0030]. Patients at an urban academic medical center received either clinical pharmacist support alone or both clinical pharmacist and CHW. CHWs conducted home visits and telephone calls with patients, based on patient availability, willingness, and needs. With permission, CHWs also accompanied patients to primary care provider (PCP) and pharmacist visits, reinforcing clinician instructions and creating plans for adherence. CHWs provided social support, diabetes education, assistance with problem‐solving, health care navigation, translation (English/Spanish), and referrals to community resources. Additionally, CHWs communicated with pharmacists in person, by telephone, and through secure e‐mail to coordinate patient management.

Randomization to these two groups was blocked by sex, ethnicity, and clinic site using a computer-generated random number generator by a research assistant. Eligibility criteria included: (1) self-identified African-American or Hispanic adult (≥21 years of age); (2) history of type 2 diabetes; (3) hemoglobin A1c (HbA1c) ≥8% in the past year; and (4) having received primary care at our institution for at least one year.

We conducted an electronic chart review and abstracted encounter data during the initial 12 months of the study, including non-urgent visits to PCPs, specialists (endocrinology, cardiology, nephrology, transplant surgery), diabetes educators, and clinical pharmacists. While patients in both groups were offered clinical pharmacist support, patient utilization of their services varied. Consequently, we assessed the number of pharmacist encounters, as CHWs may have influenced this by providing assistance with health system navigation or encouragement in attending provider appointments. To test the difference between CHW plus pharmacist and pharmacist-only groups, two-sample *t*-test or nonparametric Wilcoxon rank-sum tests for continuous variables, as well as Chi-square or Fisher exact tests for categorical variables were utilized as appropriate, respectively. Multivariate modelling with negative binominal regression were used to identify the predictors of healthcare utilization from group assignment as well as baseline demographic (age, sex, preferred language, highest education level, health insurance, employment) and comorbidity data (diabetes duration, diabetes knowledge, social support, depression, HbA1c, blood pressure, body mass index, cholesterol, insulin use, oral diabetes medication use, smoking, as well as history of myocardial infarction, stroke, end-stage renal disease, amputation, and peripheral vascular disease). All statistical tests were two-sided.

Results {#s0015}
=======

A total of 244 patients met inclusion and exclusion criteria, 120 in the CHW group and 124 in the control group ([Table 1](#t0005){ref-type="table"}). Together, the patients had a mean (standard deviation \[SD\]) age of 54 (11) years, 22% were employed, 23% had a college education, and 5.4% were uninsured [@b0030]. Of the 120 patients assigned to CHW support, 92% completed at least one CHW encounter, with an overall mean (SD) of 6.5 (5.3) CHW encounters. Aside from insurance coverage, there were no baseline differences between CHW plus pharmacist and pharmacist-only groups with regard to demographic factors or comorbidities [@b0030]. Mean (SD) diabetes duration and HbA1c were 14 (8.8) years and 9.5% (1.9) respectively [@b0030]. No differences were found in mean number of PCP (3.9 vs. 3.8, p = 0.64), specialist (1.9 vs. 1.8, p = 0.79), clinical pharmacist (4.6 vs. 4.9, p = 0.58), or diabetes educator (0.3 vs 0.5, p = 0.20) visits between CHW and pharmacist-only groups, respectively ([Table 2](#t0010){ref-type="table"}). Among patients receiving CHW support, multivariate modeling revealed that PCP visits were predicted by insulin use (incident rate \[IR\] 1.31, 95% CI 1.09--1.57), and clinical pharmacist visits by age (IR 1.02, 95% CI 1.01--1.03). Specialist visits were predicted by oral diabetes medication use (IR 0.47, 95% CI 0.28--0.77), diabetes duration (IR 1.03, 95% CI 1.01--1.06), and end-stage renal disease (IR 2.91, 95% CI 1.55--5.45).Table 1Patient demographics and characteristics.CHW + Pharmacist (N = 120)Pharmacist Alone (N = 124)*p*-valueAge, mean years ± SD53.8 ± 10.554.6 ± 11.70.61Sex (male), N (%)37 (30.8%)43 (34.7%)0.52English as primary language, N (%)105 (87.5%)103 (83.1%)0.28Education level, N (%)0.24 Less than high school33 (27.5%)39 (31.5%) High school/GED58 (48.3%)59 (47.6%) 2-year certificate/associate17 (14.2%)19 (15.3%) College graduate12 (10.0%)5 (4.0%) Graduate degree0 (0.0%)2 (1.6%)Insurance coverage, N (%)[\*](#tblfn1){ref-type="table-fn"}***0.03*** Uninsured4 (3.3%)9 (7.3%) Public aid/Medicaid79 (65.8%)58 (46.8%) Medicare17 (14.2%)31 (25.0%) Private insurance20 (16.7%)23 (18.5%)Unemployed, N (%)18 (15.0%)13 (10.5%)0.52Diabetes duration, mean years ± SD13.2 ± 8.713.7 ± 8.90.71Medication History, N (%) Insulin79 (65.8%)83 (66.9%)0.89 Oral diabetes medication87 (72.5%)92 (74.2%)0.77 Oral hypertension medication103 (85.8%)108 (87.1%)0.85Comorbidities, N (%) Current smoker26 (21.7%)25 (20.2%)0.07 History of myocardial infarction7 (5.8%)10 (8.1%)0.62 History of stroke8 (6.7%)10 (8.1%)0.81 History of end-stage renal disease14 (11.7%)17 (13.7%)0.70 History of amputation3 (2.5%)6 (4.8%)0.50 History of peripheral vascular disease8 (6.7%)8 (6.5%)1.00[^1][^2]Table 2Number of healthcare provider visits by group.CHW + Pharmacist (N = 120)Pharmacist Alone (N = 124)*p*-valuePrimary care physician, mean (SD)3.9 (2.5)3.8 (2.5)0.64Specialist physician, mean (SD)1.9 (4.0)1.8 (3.0)0.79Pharmacist, mean (SD)4.6 (4.9)4.9 (5.2)0.58Diabetes educator, mean (SD)0.3 (0.8)0.5 (1.3)0.20[^3]

Discussion {#s0020}
==========

There were no differences in non-urgent ambulatory healthcare utilization between African-American and Hispanic patients receiving versus not receiving CHW support. This finding is interesting given other evidence demonstrating that CHWs reduce healthcare costs and *preventable,* urgent health services utilization (e.g., emergency department visits and hospitalizations) [@b0020], [@b0025], [@b0035], [@b0040]. While CHWs may conceivably increase access and use of non-urgent healthcare services by encouraging medical visit attendance and addressing transportation barriers, this was not observed in the trial.

We are unaware of clinical trials designed to specifically assess ambulatory utilization in persons with diabetes receiving CHW support. However, studies assessing similar endpoints in the use of preventive services and chronic disease care have reported mixed results [@b0020]. For example, in patients with asthma, greater follow-up primary care appointments was observed with the addition of CHW support [@b0045], while other studies showed no such effect [@b0050], [@b0055]. In addition, a trial limited to uninsured Hispanic women aged 40 and older showed that CHWs increased follow-up for routine preventative exams [@b0060]. Similarly, CHW support increased both access to and usage of primary care services among patients recently discharged from the hospital setting [@b0040]. Some of the variability in evidence may relate to variation in the population studied as well as CHW training, roles, and activities [@b0065].

This study is unique in investigating non-urgent healthcare utilization in the context of CHW support. However, several limitations are present in this study. Firstly, because endpoints were limited to one year, long-term effects of CHW support may not have been captured. In addition, our patient population was limited to that of our own academic institution, which may potentially affect external validity and generalizability. Furthermore, because specialist visits were not analyzed by specific medical specialty (e.g., cardiologist vs. nephrologist), we were unable to consider potential variability in different specialist contributions and responsibilities. Moreover, we did not examine details of the nature of the outpatient encounters; thus, some encounters may have included urgent situations in addition to routine chronic disease care. Finally, because this study was a secondary analysis of a previous trial, the sample size may not be adequate to assess differences in outcomes.

In conclusion, we found no effect of CHW support on non-urgent, ambulatory healthcare utilization in low-income, minority patients with diabetes.
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[^1]: SD = Standard Deviation; CHW = Community Health Worker.

[^2]: Three patients in the control group had unknown insurance status.

[^3]: SD = Standard Deviation; CHW = Community Health Worker.
